Literature DB >> 11502881

Chinese herbal remedy wogonin inhibits monocyte chemotactic protein-1 gene expression in human endothelial cells.

Y L Chang1, J J Shen, B S Wung, J J Cheng, D L Wang.   

Abstract

Wogonin (Wog), an active component of Scutellaria baicalensis, has antioxidant and anti-inflammatory properties. Monocyte chemotactic protein-1 (MCP-1), a potent chemoattractant for monocytes, plays a crucial role in case of early inflammatory responses, including atherosclerosis. In this study, we investigated the effect of Wog on phorbol ester (PMA)-induced MCP-1 expression in human umbilical vein endothelial cells (ECs). The MCP-1 mRNA levels and MCP-1 release in Wog-treated ECs were measured. Wog inhibited PMA-induced MCP-1 mRNA levels and MCP-1 secretion in a dose-dependent manner. The inhibition of MCP-1 induction by Wog is a transcriptional event, as shown by Wog's significant reduction of both MCP-1 promoter and 4x 12-O-tetradecanoylphorbol-13-acetate response element-luciferase reporter activities. By electrophoretic mobility assay, Wog significantly reduced the AP-1 binding activity induced by PMA. Furthermore, the PMA-induced extracellular signal-regulated kinase 1/2 and c-Jun amino-terminal kinase activities that contributed to AP-1 activity and MCP-1 gene induction were obviously attenuated after pretreating ECs with Wog. The decrease of MCP-1 secretion by Wog pretreatment led to a reduction of monocyte adhesion to ECs. Taken together, our results demonstrate that Wog inhibits MCP-1 induction in ECs; this inhibition is mediated by reducing AP-1 transcriptional activity via the attenuation of ERK1/2 and JNK signal transduction pathways. We conclude that Wog has the potential therapeutic development for use in anti-inflammatory and vascular disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502881

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Wogonin ameliorates lipotoxicity-induced apoptosis of cultured vascular smooth muscle cells via interfering with DAG-PKC pathway.

Authors:  Yu-min Liu; Xiong Wang; Ahmed Nawaz; Zhao-hong Kong; Yan Hong; Chang-hua Wang; Jun-jian Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

2.  Ethanol inhibits monocyte chemotactic protein-1 expression in interleukin-1{beta}-activated human endothelial cells.

Authors:  John P Cullen; Shariq Sayeed; Ying Jin; Nicholas G Theodorakis; James V Sitzmann; Paul A Cahill; Eileen M Redmond
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-20       Impact factor: 4.733

3.  Wogonin suppresses osteopontin expression in adipocytes by activating PPARα.

Authors:  Ye-min Zhang; Ming-xin Li; Zhao Tang; Chang-hua Wang
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

4.  Glycyrrhetinic acid inhibits ICAM-1 expression via blocking JNK and NF-kappaB pathways in TNF-alpha-activated endothelial cells.

Authors:  Ying-ling Chang; Chien-lin Chen; Chao-Lin Kuo; Bor-chyuan Chen; Jyh-sheng You
Journal:  Acta Pharmacol Sin       Date:  2010-04-26       Impact factor: 6.150

5.  Wogonin improves histological and functional outcomes, and reduces activation of TLR4/NF-κB signaling after experimental traumatic brain injury.

Authors:  Chien-Cheng Chen; Tai-Ho Hung; Yen-Ho Wang; Chii-Wann Lin; Pei-Yi Wang; Chun-Yen Lee; Szu-Fu Chen
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

Review 6.  Traditional Chinese Medicine Protects against Cytokine Production as the Potential Immunosuppressive Agents in Atherosclerosis.

Authors:  Yan Ren; Wei Qiao; Dongliang Fu; Zhiwei Han; Wei Liu; Weijie Ye; Zunjing Liu
Journal:  J Immunol Res       Date:  2017-09-06       Impact factor: 4.818

Review 7.  The Effects of Chunghyul-Dan (A Korean Medicine Herbal Complex) on Cardiovascular and Cerebrovascular Diseases: A Narrative Review.

Authors:  Woo-Sang Jung; Seungwon Kwon; Seung-Yeon Cho; Seong-Uk Park; Sang-Kwan Moon; Jung-Mi Park; Chang-Nam Ko; Ki-Ho Cho
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-02       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.